<code id='CE99EB466F'></code><style id='CE99EB466F'></style>
      • <acronym id='CE99EB466F'></acronym>
      <center id='CE99EB466F'><center id='CE99EB466F'><tfoot id='CE99EB466F'></tfoot></center><abbr id='CE99EB466F'><dir id='CE99EB466F'><tfoot id='CE99EB466F'></tfoot><noframes id='CE99EB466F'>
      • <optgroup id='CE99EB466F'><strike id='CE99EB466F'><sup id='CE99EB466F'></sup></strike><code id='CE99EB466F'></code></optgroup>
        5. <b id='CE99EB466F'><label id='CE99EB466F'><select id='CE99EB466F'><dt id='CE99EB466F'><span id='CE99EB466F'></span></dt></select></label></b><u id='CE99EB466F'></u>
          <i id='CE99EB466F'><strike id='CE99EB466F'><tt id='CE99EB466F'><pre id='CE99EB466F'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / knowledge / leisure time      
           
     
           
      
          leisure time 
           
      
           
      
           
       2025-09-30 22:17:50 
   
      
           
      
           
                        
          leisure time  
          
                                   
                 
                                      author：focus   
                                        
                                      
                                      Page View：8
                                  
                                    
          
                                   
          Adam's take main illustration
          Molly Ferguson/STAT
          Biotech is awash in PIPEs.
          The numbers behind these privately negotiated purchases of public-company stock are astounding. By my count, there have been 30 PIPE transactions involving public biotechs and institutional investors (mostly hedge funds) that have raised $4 billion in the first two months of the year.
          advertisement
          Just this week, five biotechs have brought in a combined $950 million via PIPEs, including Denali Therapeutics raising $500 million, the largest such financing this year. Crinetics Pharmaceuticals raised $350 million.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          Medicare drug price negotiation hasn't dried up venture capital
                                
                            
          Next article：  
                                      
                                          Bright Health sells Medicare Advantage business to Molina
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles